Sign in Subscribe
Adults

Breakthrough in Influenza Vaccines: New Study Shows Promise in Protecting Against Pandemic Outbreaks

Strategic Insights

— 1 min read

Researchers from Otto-von-Guericke-University in Magdeburg, Germany, have conducted a phase 3 trial to evaluate the safety, tolerability, and immunogenicity of an adjuvanted H5N1 vaccine in adults with and without underlying immunosuppressive conditions. The study, published in the journal Vaccines, demonstrates the efficacy of the vaccine in inducing antibody responses in both healthy individuals and those with immunosuppressive conditions, meeting former Committee for Medicinal Products for Human Use (CHMP) criteria.

Key Takeaways:

  • The study involved 539 adults aged 18-60 and 61 years, who were further stratified into subgroups based on health status and immunosuppressive conditions.
  • The adjuvanted H5N1 vaccine (aH5N1) showed an increased antibody response in healthy individuals and those with immunosuppressive conditions, with geometric mean ratios (GMRs) of 2.5 and 2.0, respectively, in participants aged 18-60 and 61 years.
  • The vaccine had a clinically acceptable safety and tolerability profile, comparable to that observed in previous aH5N1 studies.
  • The study's findings support the viability of aH5N1 as a pre-pandemic influenza vaccine for at-risk individuals when an antigenically matched pandemic influenza vaccine is not yet available.
  • The research was funded by Csl Seqirus, and the study's lead author is Peter Malfertheiner from the Department of Gastroenterology, Hepatology and Infectious Diseases at Otto-von-Guericke-University.

Statistics:

  • 539 adults participated in the phase 3 trial, with 91 healthy individuals aged 18-60, 89 healthy individuals aged 61, 180 individuals with immunosuppressive conditions aged 18-60, and 179 individuals with immunosuppressive conditions aged 61.
  • The geometric mean ratios (GMRs) for antibody responses were 2.5 in healthy participants aged 18-60, 2.0 in healthy participants aged 61, 1.8 in individuals with immunosuppressive conditions aged 18-60, and 1.6 in individuals with immunosuppressive conditions aged 61.

Sources:

  • Research statement: "Pandemic influenza may cause substantial morbidity and mortality, especially in older adults and those with immunosuppressive conditions."
  • Research article: Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and Without Underlying Immunosuppressive Conditions. Vaccines, 2025, 13(4):379.
  • Publisher: MDPI AG
  • DOI: 10.3390/vaccines13040379
  • Contact information: Peter Malfertheiner, Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke-University, 39120 Magdeburg, Germany.

Read more